Cargando…

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy

Monotherapy with olaparib provides significant benefits over standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer, who had two or fewer previous chemotherapeutic regimens for metastatic disease. Olaparib was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumeta, Toko, Matsunuma, Ryoichi, Yamaguchi, Kei, Hayami, Ryosuke, Tsuneizumi, Michiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873165/ https://www.ncbi.nlm.nih.gov/pubmed/31762754 http://dx.doi.org/10.1159/000503858

Ejemplares similares

Acquired Treatment Resistance in a Patient with Metastatic PD-L1-Positive Breast Cancer and Germline BRCA1 Mutation
por: Kumeta, Toko, et al.
Publicado: (2023)

Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome
por: Tsuneizumi, Michiko, et al.
Publicado: (2022)

Concurrent Bowen's Disease of the Nipple and Breast Cancer
por: Yamaguchi, Kei, et al.
Publicado: (2020)

Large Breast Tumor Ulceration and Quality of Life in an 80-Year-Old Woman
por: Yamaguchi, Kei, et al.
Publicado: (2021)

Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast
por: Usui, Yuki, et al.
Publicado: (2021)

Fertility preservation before neoadjuvant chemotherapy in a premenopausal breast cancer patient: a case report
por: Kobayashi, Arika, et al.
Publicado: (2019)

Enrichment of Immune-Related Genes in Aggressive Primary Breast Angiosarcoma: A Case Report
por: Matsunuma, Ryoichi, et al.
Publicado: (2023)

Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification
por: Kota, Karthik, et al.
Publicado: (2017)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer
por: Grinshpun, Albert
Publicado: (2023)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines
por: Tan, Huining, et al.
Publicado: (2009)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers
por: Schleifman, Erica B., et al.
Publicado: (2014)

Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy
por: Kelly, Patrick, et al.
Publicado: (2017)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
por: Baldwin, Paige, et al.
Publicado: (2018)

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
por: Bianchini, Giampaolo, et al.
Publicado: (2013)

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells
por: Gattelli, Albana, et al.
Publicado: (2013)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)
por: O'Shaughnessy, J., et al.
Publicado: (2016)

Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
por: Ávila-Arroyo, Sonia, et al.
Publicado: (2015)

Estrogen Receptor Mutations and Changes in Estrogen Receptor and Progesterone Receptor Protein Expression in Metastatic or Recurrent Breast Cancer
por: Umekita, Yoshihisa, et al.
Publicado: (1998)

Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib
por: Rizvi, Wajeeha, et al.
Publicado: (2017)

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
por: Kuemmel, Sherko, et al.
Publicado: (2020)

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations
por: Dowling, Ryan J O, et al.
Publicado: (2019)

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel, Nelson, et al.
Publicado: (2017)

Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines
por: KIM, JINKYOUNG, et al.
Publicado: (2016)

Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines
por: Kim, Yun Gyoung, et al.
Publicado: (2019)

Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor‐Positive Metastatic Breast Cancer
por: Jin, Liang, et al.
Publicado: (2020)

A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer
por: Wheelden, Megan, et al.
Publicado: (2018)

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions
por: Dowling, Ryan J O, et al.
Publicado: (2019)

The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer
por: Allred, D Craig, et al.
Publicado: (2004)

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
por: Datta, Jharna, et al.
Publicado: (2022)

First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
por: Tomao, Federica, et al.
Publicado: (2020)

Cyclopia extracts act as selective estrogen receptor subtype downregulators in estrogen receptor positive breast cancer cell lines: Comparison to standard of care breast cancer endocrine therapies and a selective estrogen receptor agonist and antagonist
por: Olayoku, Folasade R., et al.
Publicado: (2023)

Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy
por: Himeji, Daisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fmfcmep08lv917hgs23c329uu8